Personalis®

Advanced Genomic Services for Inherited Disease & Cancer

Human genome sequencing and analysis with the most accurate and comprehensive end-to-end human exome and whole genome sequencing, analysis, and interpretation solutions and services for researchers and clinicians.

Home
1 855-GENOME4 (436-6634)|info@personalis.com
Click edit button to change this code.

Personalis in the news

ACE for Inherited Disease

enhance your diagnostic yield

Learn More

ACE Services for Cancer

for clinical trials and research

Learn More

ACE Research Services

the most cost-effective solution

Learn More

ACE Platform and Assays

for superior discovery & diagnosis

Learn More

Featured Download

BROCHURE
Tumor Profiling for Clinical Trials
Comprehensive Analysis, Tailored Results

The Accuracy and Content Enhanced (ACE) Advantage

See the ACE Difference
Compare the difference in coverage between a standard coverage vs. the ACE coverage
Find important data other standard exomes often miss
RPGR Gene
Depth
80
40
0
Coding Position
RPGR
  • CDKN2A
  • KCNQ1
  • MAPT
  • RPGR
  • SPRED1
  • STK11
Check the box to see the coverage.

Select a gene from the dropdown list on the right to see the difference between a standard exome coverage vs. coverage with the ACE Exome.

Menlo Park, CA – June 6, 2016 – Personalis, Inc., a leading precision medicine company focused on advanced NGS-based clinical diagnostic and research services announced today that the company has entered into a letter of intent (LOI) with Mount Sinai Services, Inc. of Toronto, Ontario, Canada, a global provider of customized clinical laboratory and research services. The LOI contains broad terms for the development of a partnership framework for Personalis and Mount Sinai Services to offer the Personalis patented, and CLIA validated ACE (Accuracy and Content Enhanced) sequencing and analysis technology for clinical diagnostic and research tumor molecular profile sequencing and analysis and immuno-oncology sequencing clinical trials for customers throughout Canada. The ACE Platform® incorporates proprietary sample prep and sequencing processes which produce the highest levels of gene finishing and coverage of difficult-to-sequence regions.

Personalis currently provides comprehensive genomic testing for tumor-profiling through its ACE CancerPlus test for solid tumors. As the largest and most comprehensive cancer panel available today, the ACE CancerPlus test combines both DNA and RNA sequencing of over 1,400 genes, using the Personalis proprietary ACE technology. The ACE CancerPlus Test result reports out on 181 genes of clinical relevance, producing comprehensive tumor genomic profile data to guide therapy and ongoing research.

The ACE ImmunoID service offers multiple solutions for the comprehensive analysis of tumor mutation burden and neoantigen identification including the leading ACE Cancer Exome and Transcriptome covering over 20,000 genes and the ACE Cancer DNA/RNA Panel available with over 1,400 genes. The Personalis ACE assays and informatics platform achieves industry leading coverage and sensitivity enabling variants to be identified more accurately and reliably in regions that may be completely missed by typical exomes, transcriptomes, and panels. The ACE assays together with advanced informatics are CLIA validated to enable clinical diagnostic and clinical trials use.

“We are pleased to work with Mount Sinai Services to offer the Personalis ACE technology to support immuno-oncology clinical trials and clinical laboratory and research tumor profiling in Canada,” said John West, CEO of Personalis. “Mount Sinai Services has been a leader in advancing personalized medicine in Canada and understands the complexities and value of comprehensive and accurate analysis and interpretation in cancer research and clinical care. Their longstanding reputation for innovation and high quality customer service provides Personalis with a technically robust partner in Canada.”

“As a leading, independent clinical diagnostic and research laboratory with a strong focus on precision medicine and diagnostics, Mount Sinai Services is delighted to work with Personalis to develop this strategic partnership to advance cancer therapeutic development and clinical care,” said Dr. Azar Azad, Managing Director of Mount Sinai Services. “We are confident that our expertise in providing customized laboratory services, combined with the capabilities of the Personalis ACE Platform will contribute to advancing translational medicine by providing a comprehensive solution for pharma discovery and development of cancer therapies, and personalized clinical diagnostic cancer care.”

About Personalis, Inc.

www.personalis.com) a leading precision medicine company focused on advanced NGS-based clinical diagnostic and research services for cancer and inherited genetic disease. The company’s ACE Exome technology is designed to obtain the most comprehensive and accurate genomic data tumor burden for tumor molecular profile and immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

About Mount Sinai Services, Inc.

Mount Sinai Services is a CAP/CLIA and ISO 15189 certified global provider of customized clinical diagnostic laboratory and research services. Mount Sinai Services works closely with world-renowned clinicians and researchers at Sinai Health System, Lunenfeld-Tanenbaum Research Institute, University of Toronto and other Canadian academic and healthcare providers to offer comprehensive services supporting discovery and innovation in the life sciences, including medical device and diagnostic assay development and validation, clinical trial management and providing customized services to biotech and pharma industry. Mount Sinai Services provides specialized clinical laboratory testing throughout Canada and supports processes to achieve new assay reimbursements.

Mount Sinai Services is committed to providing its clients with superior customer service and high-quality results based on a truly collaborative approach. For information, visit www.mountsinaiservices.com.

For more information please visit www.personalis.com.

Personalis Media Contact:
Jennifer Havlek
650-752-1300
pr@personalis.com
www.personalis.com

 

Mount Sinai Services Contact:
Azar Azad Ph.D.
Managing Director
(416) 586-4800 ext. 7266
mss@mountsinaiservices.com

Menlo Park, CA – November 17, 2015 – Personalis, Inc., a leading genomics-based clinical diagnostic laboratory, announced today that the company has entered into a partnership with the Louisiana State University Health Sciences Center New Orleans Precision Medicine Program to provide comprehensive clinical genomic testing for tumor-profiling and inherited genetic disease. “We are thrilled to work together with the LSU Health New Orleans Precision Medicine Program to provide our comprehensive, high accuracy genomic tests to their patients with cancer and genetic disorders. Working with LSU Health New Orleans, we want to provide the best possible care to patients by bringing genomics-based precision medicine to the bedside,” said Dr. Richard Chen, Chief Scientific Officer at Personalis. “Not only will this partnership bring benefits to patients, but it will also bring the substantial medical and scientific expertise at the two institutions together in a research capacity that will benefit future patients.”

Personalis will perform clinical cancer testing and research services through its ACE CancerPlus test. As the largest and most comprehensive cancer panel available today, the ACE CancerPlus test combines both DNA and RNA sequencing of over 1,300 genes and utilizes Personalis’ proprietary ACE technology to provide leading edge coverage and accuracy. Personalis’ testing will provide comprehensive tumor genomic profile data to guide therapy and ongoing research at the LSU Health New Orleans Precision Medicine Program. In addition, Personalis will provide its ACE Clinical Exome™ test for the diagnosis of genetic disorders in both pediatric and adult patients. The ACE Clinical Exome Test targets essentially all human genes using Personalis’ leading ACE exome technology. Through a multifaceted approach, including an augmented exome sequencing platform, improved informatics, and genome-wide sequence-based structural variant detection, Personalis achieves improved diagnostic yield.

“We serve as a central health care provider to a large and diverse population in Louisiana that has an equally diverse set of clinical diagnostic needs,” said Dr. Larry Hollier, Chancellor, LSU Health Sciences Center New Orleans. “We have often seen that conventional genetic diagnostic methods have been unable to provide comprehensive results, and we feel Personalis’ sophisticated approach is the future in terms of genome-scale diagnostics for inherited genetic diseases and for cancer. Our partnership with Personalis will enable us to provide the most advanced genomics tests to our patients.”

“We are very excited to be working with LSU Health New Orleans and the Precision Medicine Program on Mendelian and cancer diagnostics as well as supporting certain research efforts associated with the LSU Health New Orleans Precision Medicine Program,” said John West, CEO of Personalis. “They are at the forefront of adopting advanced genomic diagnostics for clinical care, and understand the complexities and clinical value of comprehensive and accurate analysis and interpretation.”

“The LSU Health New Orleans School of Medicine is strongly committed to clinical and translational research, particularly focused on conditions affecting the patients we serve,” noted Dr. Steve Nelson, Dean of LSU Health New Orleans School of Medicine. “The partnership with Personalis will open the way to cutting edge investigations of cancers and genetic disorders that disproportionately affect Louisiana patients.” Dr. Lucio Miele, Professor and Chair, Department of Genetics at LSU Health New Orleans School of Medicine, commented that, “Personalis and the LSU Health New Orleans Precision Medicine Program will also collaborate on various research projects that will be focused on enhancing patient care and outcomes, including the areas of immuno-oncology and liquid biopsies.”

“We look forward to a productive partnership that will result in better care for our patients and their families, especially those who have struggled to find answers that now may be within reach,” concluded LSU Health New Orleans Chancellor Dr. Hollier.

About Personalis, Inc.

Personalis, Inc. (www.personalis.com) provides clinicians and researchers advanced genome sequencing and interpretation services for cancer and inherited genetic disease. The company’s clinical laboratory is CLIA licensed and CAP accredited.

About LSUHSC

LSU Health Sciences Center New Orleans educates Louisiana’s health care professionals. The state’s health university leader, LSU Health New Orleans includes a School of Medicine, the state’s only School of Dentistry, Louisiana’s only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty takes care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSU Health New Orleans research enterprise generates jobs and enormous economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit www.lsuhsc.edu, twitter.com/LSUHSCHealth or facebook.com/LSUHSC.

About the LSU Health New Orleans Center for Precision Medicine

The NCI-funded Gulf South National Institute of Health Community Oncology Research Program (NCORP), led by Dr. Augusto Ochoa, is designed to allow NCORP investigators to design genomics-based clinical trials tailored to Louisiana and Mississippi patients.

Personalis Media Contact:
Jennifer Havlek
650-752-1300
pr@personalis.com
www.personalis.com

Menlo Park, CA and Baltimore, MD | October 8, 2015 – Personalis, Inc., a leading genomics-based service provider, today announced it is expanding its services to immuno-oncology research and clinical trials with its ACE ImmunoID product. ACE ImmunoID is based on the Personalis ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. “Immuno-oncology therapies are tremendously promising, but understanding which biomarkers modulate response to treatment is the next crucial step. Our ACE ImmunoID assays, optimized and validated for cancer, are ideal for immuno-oncology studies that require broad neoantigen detection and gene expression analysis to complement DNA variant analysis,” says Dr. Richard Chen, Chief Scientific Officer of Personalis. Scientists from Personalis are presenting at the 2015 American Society of Human Genetics Annual Meeting taking place in Baltimore, MD.

Next-generation sequencing is increasingly used to support immuno-oncology studies. However, typical NGS cancer offerings fall short for immuno-oncology in a number of areas including sequence biases, gaps in gene coverage, narrow gene footprint, limited validation studies, lack of support for paired tumor/normal analysis, and lack of integrated RNA analysis. Personalis addresses these issues with proprietary Accuracy and Content Enhanced (ACE) technology to improve cancer panel, exome, and transcriptome sequencing. ACE fills in systematic NGS sequencing gaps through Personalis’ enhanced targeted enrichment approach which optimizes sample prep and targeted capture in difficult to sequence regions such as regions of high-GC content. The ACE cancer exome and ACE cancer panel augment over 1600 cancer and immuno-oncology genes as well as key non-coding regions. High coverage ACE sequencing data provides sensitive detection of small variants and CNVs at low allele frequencies. In addition, RNA data from the same sample, targeted to the same gene set, is used to quantify gene expression—critical for immune-oncology applications—in addition to detecting gene fusions and confirming allelic expression. ACE ImmunoID features leading edge informatics pipelines supporting both RNA and DNA analysis as well as tumor normal analysis to aid in the detection of neoantigens. “We recognize the enormous importance of immuno-oncology research and are excited to be launching a comprehensive and accurate solution for our pharmaceutical, biotech and academic customers,” says John West, CEO of Personalis.

More information, including a comprehensive brochure detailing these new offerings can be found at:
www.personalis.com/cancer/ace-services-for-immuno-oncology/

About Personalis, Inc.

Personalis, Inc. provides researchers and clinicians advanced genome-scale sequencing and interpretation services for inherited genetic disease and cancer. The company’s clinical laboratory is CLIA licensed and CAP accredited.

For more information about Personalis, Inc., please visit www.personalis.com.

Personalis Media Contact:
Jennifer Havlek
650-752-1300
pr@personalis.com
www.personalis.com
Menlo Park, CA – March 23, 2015 – Personalis, Inc., a leading genomics-based clinical diagnostic laboratory, announced today that the company will be present results demonstrating the application of new technologies to enhance the diagnostic yield of clinical exome testing at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, March 24-28, 2015, in Salt Lake City, Utah

Through multiple venues, including invited oral and poster presentations as well as a company-sponsored workshop, scientists and clinicians from Personalis will showcase how a multidisciplinary approach to improving diagnostic yield has proven successful in solving the most challenging Mendelian disorder cases. Covering the use of improved informatics, mosaic variant identification strategies, sequence-based structural variant detection, and a content and coverage enhanced exome platform, the talks and posters will demonstrate why a multifaceted approach is critical to achieving a high diagnostic yield.

John West, President and CEO of Personalis said, “Our team has been working hard to advance every aspect of the technologies required to provide diagnoses for genetic disease. The breadth of presentations at ACMG demonstrates both the complexities of solving the most difficult cases, as well as how an investment in improving technologies can provide meaningful answers for patients and their families.”

A detailed listing of Personalis presentations at the ACMG meeting can be found at: www.personalis.com/acmg2015/

Information about the ACE Clinical Exome Test can be found at: www.personalis.com/clinical/

About Personalis, Inc.
Personalis, Inc. provides researchers and clinicians advanced genome-scale sequencing and interpretation services for inherited genetic disease and cancer. The company’s clinical laboratory is CLIA licensed and CAP accredited.

For more information please visit www.personalis.com.

Personalis Media Contact:
Paul Moon
650-752-1300
pr@personalis.com
www.personalis.com